Myeloid venetoclax resistance observed in CLL patients

An Australian haematologist is backing time-limited therapy after his research showed long-term venetoclax (Venclexta) use could drive drug resistance in myeloid cells. A study of 89 chronic lymphocytic leukaemia (CLL) patients on median 75 months’ venetoclax showed prolonged BCL2 inhibitor use could give rise to anti-apoptotic myeloid BAX mutations — a potentially significant adaptation for ...

Already a member?

Login to keep reading.

© 2021 the limbic